文献速递心律失常

氟卡尼降低儿茶酚胺敏感性多形性室速患者心律失常事件发生率

Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.
PubMed 文献 · Circulation · 2023-10-27

该多中心病例交叉研究纳入247例临床或基因诊断的儿茶酚胺敏感性多形性室速患者,在β受体阻滞剂基础上加用氟卡尼。中位随访显示,加用氟卡尼后心律失常事件年发生率从5.6%降至4.0%,发生率比0.55(95%CI 0.38-0.83,P=0.007),在既往有症状及β受体阻滞剂治疗期间仍有突破事件的患者中获益更显著。

要点

  • 在β受体阻滞剂基础上加用氟卡尼与心律失常事件发生率显著降低相关。
  • 既往有症状患者及β受体阻滞剂治疗期间仍有事件者获益更明显。
  • 氟卡尼可作为β受体阻滞剂保护不足患者的附加治疗选择。

核心结论

  • 在儿茶酚胺敏感性多形性室速患者中,β受体阻滞剂基础上加用氟卡尼与心律失常事件发生率降低相关。

研究设计与样本

  • 多中心病例交叉研究,来自2个国际注册登记,纳入247例临床或基因诊断的儿茶酚胺敏感性多形性室速患者。
  • 研究期间定义为背景治疗(β受体阻滞剂类型、左心交感神经去支配、植入式心律转复除颤器治疗状态)保持不变,分为氟卡尼前和氟卡尼治疗期间。
  • 采用广义线性混合模型(负二项分布,患者随机效应)评估氟卡尼与心律失常事件率的关联。

主要发现

  • 氟卡尼前中位随访2.1年(IQR 0.4-7.2),41例(17%)发生58次心律失常事件,年事件率5.6%。
  • 氟卡尼治疗期间中位随访2.9年(IQR 1.0-6.0),23例(9%)发生38次心律失常事件,年事件率4.0%。
  • 加用氟卡尼后心律失常事件显著减少,发生率比0.55(95%CI 0.38-0.83;P=0.007)。
  • 诊断前或氟卡尼前有症状患者(n=167)中,氟卡尼与心律失常事件显著减少相关,发生率比0.49(95%CI 0.31-0.77;P=0.002)。
  • β受体阻滞剂治疗期间至少1次心律失常事件患者(n=41)中,加用氟卡尼与心律失常事件显著减少相关,发生率比0.25(95%CI 0.14-0.45;P<0.001)。

关键数值与推荐

  • 氟卡尼起始中位年龄18岁(IQR 14-29),中位剂量2.2 mg/kg/天(IQR 1.7-3.1)。
  • 基线时所有患者使用β受体阻滞剂,70例(28%)有植入式心律转复除颤器,21例(9%)有左心交感神经去支配。

临床怎么用

  • 对于β受体阻滞剂保护不足的儿茶酚胺敏感性多形性室速患者,可考虑加用氟卡尼以降低心律失常事件风险。
  • 尤其适用于既往有症状或β受体阻滞剂治疗期间仍有突破事件的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In severely affected patients with catecholaminergic polymorphic ventricular tachycardia, beta-blockers are often insufficiently protective. The purpose of this study was to evaluate whether flecainide is associated with a lower incidence of arrhythmic events (AEs) when added to beta-blockers in a large cohort of patients with catecholaminergic polymorphic ventricular tachycardia. METHODS: From 2 international registries, this multicenter case cross-over study included patients with a clinical or genetic diagnosis of catecholaminergic polymorphic ventricular tachycardia in whom flecainide was added to beta-blocker therapy. The study period was defined as the period in which background therapy (ie, beta-blocker type [beta1-selective or nonselective]), left cardiac sympathetic denervation, and implantable cardioverter defibrillator treatment status, remained unchanged within individual patients and was divided into pre-flecainide and on-flecainide periods. The primary end point was AEs, defined as sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter defibrillator shock, and arrhythmic syncope. The association of flecainide with AE rates was assessed using a generalized linear mixed model assuming negative binomial distribution and random effects for patients. RESULTS: A total of 247 patients (123 [50%] females; median age at start of flecainide, 18 years [interquartile range, 14-29]; median flecainide dose, 2.2 mg/kg per day [interquartile range, 1.7-3.1]) were included. At baseline, all patients used a beta-blocker, 70 (28%) had an implantable cardioverter defibrillator, and 21 (9%) had a left cardiac sympathetic denervation. During a median pre-flecainide follow-up of 2.1 years (interquartile range, 0.4-7.2), 41 patients (17%) experienced 58 AEs (annual event rate, 5.6%). During a median on-flecainide follow-up of 2.9 years (interquartile range, 1.0-6.0), 23 patients (9%) experienced 38 AEs (annual event rate, 4.0%). There were significantly fewer AEs after initiation of flecainide (incidence rate ratio, 0.55 [95% CI, 0.38-0.83]; P=0.007). Among patients who were symptomatic before diagnosis or during the pre-flecainide period (n=167), flecainide was associated with significantly fewer AEs (incidence rate ratio, 0.49 [95% CI, 0.31-0.77]; P=0.002). Among patients with ≥1 AE on beta-blocker therapy (n=41), adding flecainide was also associated with significantly fewer AEs (incidence rate ratio, 0.25 [95% CI, 0.14-0.45]; P<0.001). CONCLUSIONS: For patients with catecholaminergic polymorphic ventricular tachycardia, adding flecainide to beta-blocker therapy was associated with a lower incidence of AEs in the overall cohort, in symptomatic patients, and particularly in patients with breakthrough AEs while on beta-blocker therapy.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Bergeman AT, Lieve KVV, Kallas D, et al. Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation. 2023. PMID: 37886885. doi:10.1161/CIRCULATIONAHA.123.064786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。